Biosimilar Clinical Trials Face Enrollment Challenges
Executive Summary
Education for investigators and patients about the biosimilar development process, including what’s already known about a product being studied, could help trial recruitment, FDA, industry and patient reps say.
You may also be interested in...
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
FDA panelists' confusion over biosimilarity and overwhelming approval endorsements following glowing agency reviews suggest the meetings may not be having much impact on FDA deliberations; however, agency sees an opportunity to learn from what its external experts don't understand about biosimilars.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.